The t(11;20)(p15;q11∼12) translocation is a very rare but recurrent cytogenetic aberration that occurs in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). This translocation was shown to form a fusion gene between NUP98 at 11p15 and TOP1 at 20q12. Here, we describe a new case of de novo AML M2 with t(11;20) which was associated with another balanced translocation. An 81-year-old man was admitted to undergo salvage therapy for relapsed AML. G-banding and spectral karyotyping showed 46,XY,t(2;5)(q33;q31),t(11;20)(p15;q12)[20]. Expression of the NUP98/TOP1 fusion transcript was confirmed: NUP98 exon 13 was in-frame fused with TOP1 exon 8. The reciprocal TOP1/NUP98 fusion transcript was also detected: TOP1 exon 7 was fused with NUP98 exon 14. After achieving hematological complete remission, the karyotype converted to 46,XY,t(2;5)(q33;q31)[19]/46,sl,t(11;20)(p15;q12)[1]. FISH analysis demonstrated that the 5q31 breakpoint of t(2;5) was centromeric to EGR1. In all 10 cases described in the literature, the NUP98 exon 13/TOP1 exon 8 fusion transcript was expressed, indicating that it may be responsible for the pathogenesis of MDS/AML with t(11;20). On the other hand, the TOP1/NUP98 transcript was coexpressed in 4 cases of de novo AML, but not in 3 cases of therapy-related MDS. Thus, this reciprocal fusion may be associated with progression to AML.

Keywords:
Coexpression, De novo acute myeloid leukemia, Myelodysplastic syndrome, NUP98, TOP1
1.
Ahuja HG, Felix CA, Aplan PD: The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 94:3258-3261 (1999).
2.
Ahuja HG, Felix CA, Aplan PD: Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer 29:96-105 (2000).
3.
Chen S, Xue Y, Chen Z, Guo Y, Wu Y, Pan J: Generation of the NUP98-TOP1 fusion transcript by the t(11;20)(p15;q11) in a case of acute monocytic leukemia. Cancer Genet Cytogenet 140:153-156 (2003).
4.
Dambruoso I, Boni M, Rossi M, Zappasodi P, Calvello C, et al: Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome. Cancer Genet 205:285-294 (2012).
5.
Gurevich RM, Aplan PD, Humphries RK: NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. Blood 104:1127-1136 (2004).
6.
Haimi M, Avivi I, Moustafa N, Aboleil O, Gershoni-Baruch R: Treatment-related acute myeloid leukemia characterized by t(11;20)(p15;q11) and del(9)(q22). Cancer Genet Cytogenet 167:186-188 (2006).
7.
Hoffman MW, Janney S, Batanian JR: Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome. Cancer Genet Cytogenet 191:106-108 (2009).
8.
Iwase S, Akiyama N, Sekikawa T, Saito S, Arakawa Y, et al: Both NUP98/TOP1 and TOP1/NUP98 transcripts are detected in a de novo AML with t(11;20)(p15;q11). Genes Chromosomes Cancer 38:102-105 (2003).
9.
Kakazu N, Shinzato I, Arai Y, Gotoh S, Matsushita A, et al: Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b). Int J Hematol 74:53-57 (2001).
10.
Kearney L: NUP98 (nucleoporin 98 kDa). Atlas Genet Cytogenet Oncol Haematol 6:191-193 (2002).
11.
Kobzev YN, Martinez-Climent J, Lee S, Chen J, Rowley JD: Analysis of translocations that involve the NUP98 gene in patients with 11p15 chromosomal rearrangements. Genes Chromosomes Cancer 41:339-352 (2004).
12.
Mitelman F, Johansson B, Mertens F: Mitelman database of chromosome aberrations and gene fusions in cancer (2016). Available from http://cgap.nci.nih.gov/Chromosomes/Mitelman.
13.
Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, et al: Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 12:154-158 (1996).
14.
Nebral K, König M, Schmidt HH, Lutz D, Sperr WR, et al: Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. Haematologica 90:746-752 (2005).
15.
Panagopoulos I, Fioretos T, Isaksson M, Larsson G, Billström R, et al: Expression of NUP98/TOP1, but not of TOP1/NUP98, in a treatment-related myelodysplastic syndrome with t(10;20;11)(q24;q11;p15). Genes Chromosomes Cancer 34:249-254 (2002).
16.
Potenza L, Sinigaglia B, Luppi M, Morselli M, Saviola A, et al: A t(11;20)(p15;q11) may identify a subset of nontherapy-related acute myelocytic leukemia. Cancer Genet Cytogenet 149:164-168 (2004).
17.
Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, et al: NUP98 rearrangements in hematopoietic malignancies: a study of the Group Francophone de Cytogénétique Hématologique. Leukemia 20:696-706 (2006).
18.
Slape C, Aplan PD: The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma 45:1341-1350 (2004).
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.